BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15026362)

  • 1. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma.
    Movassagh M; Spatz A; Davoust J; Lebecque S; Romero P; Pittet M; Rimoldi D; Liénard D; Gugerli O; Ferradini L; Robert C; Avril MF; Zitvogel L; Angevin E
    Cancer Res; 2004 Mar; 64(6):2192-8. PubMed ID: 15026362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.
    Elliott B; Scolyer RA; Suciu S; Lebecque S; Rimoldi D; Gugerli O; Musat E; Sharma RN; Lienard D; Keilholz U; Testori A; Eggermont A; MacKie R; Robert C; Cook M; Thompson JF; Angevin E; Spatz A;
    Clin Cancer Res; 2007 Jul; 13(13):3825-30. PubMed ID: 17606713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor.
    Ladányi A; Kiss J; Somlai B; Gilde K; Fejos Z; Mohos A; Gaudi I; Tímár J
    Cancer Immunol Immunother; 2007 Sep; 56(9):1459-69. PubMed ID: 17279413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
    Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome.
    Mohos A; Sebestyén T; Liszkay G; Plótár V; Horváth S; Gaudi I; Ladányi A
    J Transl Med; 2013 Feb; 11():43. PubMed ID: 23418928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine expression and dendritic cell density in melanoma sentinel nodes.
    Botella-Estrada R; Dasí F; Ramos D; Nagore E; Herrero MJ; Giménez J; Fuster C; Sanmartín O; Guillén C; Aliño S
    Melanoma Res; 2005 Apr; 15(2):99-106. PubMed ID: 15846142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of CCL19 by DC-Lamp+ mature dendritic cells in human lymph node versus chronically inflamed skin.
    Katou F; Ohtani H; Nakayama T; Nagura H; Yoshie O; Motegi K
    J Pathol; 2003 Jan; 199(1):98-106. PubMed ID: 12474232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
    Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
    J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
    Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
    J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
    Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
    Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
    Thurner B; Haendle I; Röder C; Dieckmann D; Keikavoussi P; Jonuleit H; Bender A; Maczek C; Schreiner D; von den Driesch P; Bröcker EB; Steinman RM; Enk A; Kämpgen E; Schuler G
    J Exp Med; 1999 Dec; 190(11):1669-78. PubMed ID: 10587357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
    Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
    Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma.
    Oosterhoff D; Sluijter BJ; Hangalapura BN; de Gruijl TD
    Curr Top Microbiol Immunol; 2012; 351():181-220. PubMed ID: 21681685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.
    Jonuleit H; Giesecke-Tuettenberg A; Tüting T; Thurner-Schuler B; Stuge TB; Paragnik L; Kandemir A; Lee PP; Schuler G; Knop J; Enk AH
    Int J Cancer; 2001 Jul; 93(2):243-51. PubMed ID: 11410873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes.
    Straten Pt; Dahl C; Schrama D; Pedersen LØ; Andersen MH; Seremet T; Bröcker EB; Guldberg P; Becker JC
    Cancer Immunol Immunother; 2006 May; 55(5):495-502. PubMed ID: 16001163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
    van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity.
    Watanabe S; Kagamu H; Yoshizawa H; Fujita N; Tanaka H; Tanaka J; Gejyo F
    J Immunol; 2003 Dec; 171(11):5828-36. PubMed ID: 14634092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.